Experienced in Primary Immunodeficiency (PID)

Dr. Roni Tamari

Hematology Oncology | Hematology | Oncology
Mskcc Clinical Practice Plan
1275 York Ave, 
New York, NY 
Offers Telehealth
19 Years of Experience
Experienced in Primary Immunodeficiency (PID)
Mskcc Clinical Practice Plan
1275 York Ave, 
New York, NY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Roni Tamari is a Hematologist Oncology specialist and a Hematologist in New York, New York. Dr. Tamari has been practicing medicine for over 19 years and is rated as an Experienced provider by MediFind in the treatment of Primary Immunodeficiency (PID). Her top areas of expertise are Myelodysplastic Syndrome (MDS), Myelofibrosis, Graft Versus Host Disease (GvHD), Bone Marrow Transplant, and Colonoscopy.

Her clinical research consists of co-authoring 98 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in NY
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Capital District Physicians Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health First
  • HMO
  • POS
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Northwell Health
  • INSURANCE PLAN
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 13 Less Insurance Carriers -

Locations

MSKCC CLINICAL PRACTICE PLAN
1275 York Ave, New York, NY 10065

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Allogeneic Hematopoietic Stem Cell Transplantation of α/β T-Lymphocyte Depleted Graft Conditioned With a Reduced Intensity Regimen in Patients With Hematologic Malignancies and Aplastic Anemia
Allogeneic Hematopoietic Stem Cell Transplantation of α/β T-Lymphocyte Depleted Graft Conditioned With a Reduced Intensity Regimen in Patients With Hematologic Malignancies and Aplastic Anemia
Enrollment Status: Active_not_recruiting
Publish Date: August 19, 2025
Intervention Type: Drug, Procedure, Radiation
Study Drugs: Antithymocyte globulin, Fludarabine, Cyclophosphamide, Rituxan
Study Phase: Phase 1
A Phase II Study of Ruxolitinib Pre-, During- and Post-Hematopoietic Stem Cell Transplantation for Patients With Primary or Secondary Myelofibrosis.
A Phase II Study of Ruxolitinib Pre-, During- and Post-Hematopoietic Stem Cell Transplantation for Patients With Primary or Secondary Myelofibrosis.
Enrollment Status: Completed
Publish Date: July 29, 2025
Intervention Type: Drug
Study Drug: Ruxolitinib
Study Phase: Phase 2
A Single Arm Phase II Trial of Maintenance Low Dose 5'-Azacitidine Post T Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Myelodysplastic Syndrome and Acute Myelogenous Leukemia With High Risk for Post-Transplant Relapse
A Single Arm Phase II Trial of Maintenance Low Dose 5'-Azacitidine Post T Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Myelodysplastic Syndrome and Acute Myelogenous Leukemia With High Risk for Post-Transplant Relapse
Enrollment Status: Completed
Publish Date: May 22, 2024
Intervention Type: Drug
Study Drug: Azacitidine
Study Phase: Phase 2
Ph 1 Study of Escalating Single & Multiple Doses of Mana 312 (Multi Tumor-Associated Antigen T Cells) Administered to Adult Subjects With Acute Myeloid Leukemia or Myelodysplastic Syndrome After Allogeneic Hematopoietic Stem Cell Transplant
Ph 1 Study of Escalating Single & Multiple Doses of Mana 312 (Multi Tumor-Associated Antigen T Cells) Administered to Adult Subjects With Acute Myeloid Leukemia or Myelodysplastic Syndrome After Allogeneic Hematopoietic Stem Cell Transplant
Enrollment Status: Terminated
Publish Date: June 18, 2023
Intervention Type: Biological
Study Drug: Mana 312
Study Phase: Phase 1
A Multi-Center, Phase II Cross-sectional Study Investigating Quality of Life in Older vs. Younger Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndromes: a Companion Study to the CIBMTR 10-CMSMDS-1-Approved Expanded Access Study
A Multi-Center, Phase II Cross-sectional Study Investigating Quality of Life in Older vs. Younger Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndromes: a Companion Study to the CIBMTR 10-CMSMDS-1-Approved Expanded Access Study
Enrollment Status: Completed
Publish Date: December 02, 2020
Intervention Type: Behavioral
Phase II Trial of T-cell Depleted Hematopoietic Stem Cell Boosts Without Conditioning for Poor Marrow Graft Function Following Allogeneic Hematopoietic Stem Cell Transplantation
Phase II Trial of T-cell Depleted Hematopoietic Stem Cell Boosts Without Conditioning for Poor Marrow Graft Function Following Allogeneic Hematopoietic Stem Cell Transplantation
Enrollment Status: Terminated
Publish Date: October 09, 2018
Intervention Type: Procedure, Device
Study Phase: Phase 2
View 5 Less Clinical Trials

95 Total Publications

Bone marrow and blood demonstrate distinct immune reconstitution patterns and correlations with relapse post-transplant.
Bone marrow and blood demonstrate distinct immune reconstitution patterns and correlations with relapse post-transplant.
Journal: Blood advances
Published: December 13, 2024
Similar Doctors
Distinguished in Primary Immunodeficiency (PID)
Dr. Adriana C. Rossi
Oncology | Hematology | Hematology Oncology
Distinguished in Primary Immunodeficiency (PID)
Dr. Adriana C. Rossi
Oncology | Hematology | Hematology Oncology

Icahn School Of Medicine At Mount Sinai

10 E 102nd St, Tisch Dept Of Mount Sinai, 
New York, NY 
 (1.9 miles away)
212-844-8288
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Adriana Rossi is an Oncologist and a Hematologist in New York, New York. Dr. Rossi is rated as a Distinguished provider by MediFind in the treatment of Primary Immunodeficiency (PID). Her top areas of expertise are Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Smoldering Multiple Myeloma, Bone Marrow Transplant, and Bone Marrow Aspiration.

Advanced in Primary Immunodeficiency (PID)
Dr. Allyson Flower
Hematology | Oncology
Advanced in Primary Immunodeficiency (PID)
Dr. Allyson Flower
Hematology | Oncology

Bradhurst Avenue Specialty Office

19 Bradhurst Avenue, 
Hawthorne, NY 
 (23.8 miles away)
914-614-4270
Languages Spoken:
English
See accepted insurances

Allyson Flower is a Hematologist and an Oncologist in Hawthorne, New York. Dr. Flower is rated as an Advanced provider by MediFind in the treatment of Primary Immunodeficiency (PID). Her top areas of expertise are Myelodysplastic Syndrome (MDS), Primary Immunodeficiency (PID), Sickle Cell Disease, Bone Marrow Transplant, and Bone Marrow Aspiration.

Mitchell Cairo
Advanced in Primary Immunodeficiency (PID)
Dr. Mitchell Cairo
Hematology | Oncology
Advanced in Primary Immunodeficiency (PID)
Dr. Mitchell Cairo
Hematology | Oncology

Bradhurst Avenue Specialty Office

19 Bradhurst Avenue, 
Hawthorne, NY 
 (23.8 miles away)
914-614-4270
Languages Spoken:
English
See accepted insurances

Mitchell Cairo is a Hematologist and an Oncologist in Hawthorne, New York. Dr. Cairo is rated as an Elite provider by MediFind in the treatment of Primary Immunodeficiency (PID). His top areas of expertise are Burkitt Lymphoma, B-Cell Lymphoma, Primary Mediastinal B-Cell Lymphoma (PMBCL), Non-Hodgkin Lymphoma, and Bone Marrow Transplant.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Tamari's expertise for a condition
ConditionClose
View All 15 Advanced Conditions
View All 61 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile